Mobilization of Myeloma Cells Involves SDF-1/CXCR4 Signaling and Downregulation of VLA-4

Stem Cells

Volumn 22, Issue 1, 2004, Pages 65-73

  Gazitt, Yair ^a   Akay, Cagla ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Mobilization; Myeloma; SDF 1 CXCR4; VLA4

Indexed keywords

CELL ADHESION MOLECULE; CHEMOKINE RECEPTOR CXCR4; CYCLOPHOSPHAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 6; STROMAL CELL DERIVED FACTOR 1; VERY LATE ACTIVATION ANTIGEN 4; VERY LATE ACTIVATION ANTIGEN 5;

APHERESIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CELL ADHESION; CELL CULTURE; CELL ISOLATION; CELL MIGRATION; CELL MOTILITY; CHEMOTAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE DISRUPTION; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS;

EID: 0348141711     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.22-1-65     Document Type: Article

References (64)

1. Vora AJ, Toh CH, Peel J et al. Use of granulocyte colony-stimulating factor (G-CSF) for mobilizing peripheral blood stem cells: risk of mobilizing clonal myeloma cells in patients with bone marrow infiltration. Br J Haematol 1994;86:180-182.
2. Bensinger W, Singer J, Appelbaum F et al. Autologous transplantation with peripheral blood mononuclear cells after administration of G-CSF. Blood 1993;81:3158-3163.
3. Chao NJ, Schriber JR, Grimes K et al. Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993;81:2031-2038.
4. Lane TA, Law P, Maruyama M et al. Harvesting and enrichment of HPC mobilized into the peripheral blood of normal donors by GM-CSF or G-CSF: potential role in allogeneic transplantation. Blood 1995;85:275-282.
5. Watts MJ, Sullivan AM, Jamieson E et al. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol 1997;15:535-546.
6. Gazitt Y, Freytes CO, Callander N et al. Successful PBSC mobilization with high dose G-CSF for patients failing a first round of mobilization. J Hematother 1999;8:173-183.
7. Peters WP, Rosner G, Ross M et al. Comparative effect of GM-CSF and G-CSF on priming of peripheral blood progenitor cells for use with autologous bone marrow after high dose chemotherapy. Blood 1993;81:1709-1719.
8. Lane TA, Ho AD, Bashey A et al. Mobilization of blood-derived stem and progenitor cells in normal subjects by granulocyte-macrophage- and granulocyte-colony-stimulating factors. Transfusion 1999;39:39-47
9. Gazitt Y. Immunological profiles of effector cells and peripheral blood stem cells mobilized with different growth factors. STEM CELLS 2001;18:390-398.
10. Gazitt Y. Recent developments in the regulation of peripheral blood stem cell mobilization. J Hematother Stem Cell Res 2001;10:229-236
11. Gazitt Y. Comparison between granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the mobilization of peripheral blood stem cells. Curr Opin Hematol 2002;9:190-198.
12. Petit I, Szyper-Kravitz M, Nagler A et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002;3:687-694.
13. Lapidot T, Kollet O. The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m (null) mice. Leukemia 2002;16:1992-2003.
14. Lapidot T, Petit I. Current understanding of stem cell mobilization. The roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 2002;30:973-981.
15. Sharp JG, Joshi SS, Armitage JO et al. Significance of detection of occult non-Hodgkin's lymphoma in histologically uninvolved bone marrow by aculture technique. Blood 1992;79:1074-1080.
16. Dreyfus F, Ribrag V, Leblond V et al. Detection of malignant B cells in peripheral blood stem cell collections after chemotherapy in patients with multiple myeloma. Bone Marrow Transplant 1995;15:707-712.
17. + stem cells and lymphoma cells in non-Hodgkin's lymphoma patients mobilized with cyclophosphamide with different growth factors. J. Hematother Stem Cell Res 2001;10:167-176.
18. + stem cells do not contain clonal myeloma cells. Blood 1995;86:381-389.
19. Gazitt Y, Tian E, Barlogie B et al. Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and GM-CSF. Blood 1996;87:805-811.
20. Gazitt Y, Reading C. Autologous transplantation with tumor-free graft: a model for multiple myeloma patients. Leuk Lymphoma 1996;27:202-212.
21. Tricot G, Gazitt Y, Leemhuis T et al. Collection, engraftment kinetics and tumor contamination of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma. Blood 1998;91:4489-4495.
22. Moss TJ, Cairo M, Santana VM et al. Clonogenic circulating BM cells: implications regarding peripheral stem cell transplantation. Blood 1994;83:3085-3090.
23. Brugger W, Bross KJ, Glatt M et al. Mobilization of tumor cells and hematopoietic stem cells into peripheral blood of patients with solid tumors. Blood 1994;83:636-640.
24. Shpall EJ, Jones R. Release of tumor cells from bone marrow. Blood 1994;83:623-628.
25. Robledo MM, Sanz-Rodriguez F, Hidalgo A et al. Differential use of VLA-4 and -5 integrins by hematopoietic precursors and myeloma cells to adhere to bone marrow stroma. J Biol Chem 1998;273:12056-12060.
26. Okada T, Hawley RG, Kodaka M et al. Significance of VLA-4-VCAM-1 interaction and CD44 for transendothelial invasion in a bone marrow metastatic myeloma model. Clin Exp Metastasis 1999;17:623-629.
27. Damiano JS, Cress AE, Hazlehurst LA et al. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999;93:1658-1667.
28. Choi SJ, Oba Y, Gazitt Y et al. Antisense inhibition of macrophage inflammatory protein-1-alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest 2001;108:1833-1841.
29. Sanz-Rodríguez F, Hidalgo A, Teixidó J. Chemokine stromal cell-derived factor-1 modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood 2001;97:346-351.
30. Libura J, Drukala J, Majka M et al. CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood 2002;100:2597-2606.
31. Taichman RS, Cooper C, Keller ET et al. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002;62:1832-1837.
32. Schrader AJ, Lechner O, Templin M et al. CXCR4/CXCL12 expression and signaling in kidney cancer. Br J Cancer 2002;86:1250-1256.
33. Payne AS, Cornelius LA. The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatol 2002;118:915-922.
34. Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath BM stromal cells. Blood 1999;94:3658-3667.
35. Burger JA, Kipps TJ. Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leuk Lymphoma 2002;43:461-466.
36. Majka M, Pituch-Noworolska A, Drukala J et al. SDF-1/ CXCR4 interactions are crucial in the migration and survival of chronic lymphocytic leukemia cells in the bone marrow microenvironment. Blood 2002;100:381a.
37. Durig J, Schmucker U, Duhrsen U. Differential expression of chemokine receptors in B cell malignancies. Leukemia 2001;15:752-756.
38. Donnard M, Trimoreau F, Jaccard A et al. Chemokines receptor expression profile in low grade non Hodgkin lymphoma with leukemic phase. Blood 2002;100:349a.
39. + haemopoietic cells. Leukemia 2000;14:1652-1660.
40. Mohle R, Schittenhelm M, Failenschmid C et al. Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia. Br J Haematol 2000;110:563-572.
41. Shen W, Bendall LJ, Gottlieb DJ et al. The chemokine receptor CXCR4 enhances integrin-mediated in vitro adhesion and facilitates engraftment of leukemic precursor-B cells in the bone marrow. Exp Hematol 2001;29:1439-1447.
42. Hideshima T, Chauhan D, Hayashi T et al. The biological sequelae of stromal cell-derived factor-1 alpha in multiple myeloma. Mol Cancer Ther 2002;1:539-544.
43. Moller C, Stromberg T, Juremalm M et al. Expression and function of chemokine receptors in human multiple myeloma. Leukemia 2003;17:203-210.
44. Bertolini F, Dell'Agnola C, Mancuso P et al. CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Res 2002;62:3106-3112.
45. Lagneaux L, Delforge A, Dejeneffe M et al. Antagonists of the chemokine receptor CXCR4 block chemotaxis and inhibit stromal dependent proliferation of acute lymphoblastic leukemia cells. Blood 2002;100:762a.
46. Boehmler AM, Kuci S, Seitz G et al. In vitro and preclinical activity of the novel AMD3100 CXCR4 antagonist in lymphoma models. Blood 2002;100:579a.
47. Schwarz MK, Wells TN. New therapeutics that modulate chemokine networks. Nat Rev Drug Discov 2002;1:347-358.
48. Gazitt Y, Akay C, Thomas C et al. The role of adhesion molecules and CXCR4/SDF-1 axis in mobilization of malignant myeloma cells. Cancer Res 2003,94:524a.
49. + cells in mobilized peripheral blood of non-Hodgkin's lymphoma patients. STEM CELLs 2001;19:134-143.
50. Gazitt Y. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma pts and is not cytotoxic to hematopoietic stem cells. Leukemia 1999;13:1817-1824.
51. 2/M cell cycle arrest, activation of caspase-8 or caspase-9 and synergy with APO2/TRAIL. Blood 2003;101:4078-4087.
52. + cells in mobilized peripheral blood of non-Hodgkin's lymphoma patients. STEM CELLS 2001;19:37-45.
53. Forster R, Kremmer E, Schubel A et al. Intracellular and surface expression of HIV-1 co-receptor CXCR4/fusin on various leukocytes subsets: rapid internalization and recycling upon activation. J Immunol 1998;160:1522-1531.
54. Peled A, Petit I, Kollet O et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999;283:845-848.
55. + cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood 2000;95:3289-3296.
56. Odemis V, Moepps B, Gierschik P et al. Interleukin-6 and cAMP induce stromal cell-derived factor-1 chemotaxis in astroglia by up-regulating CXCR4 cell surface expression. J Biol Chem 2002;277:39801-39808.
57. Jourdan M, De Vos J, Mechti N et al. Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1. Cell Death Diff 2000;7:1244-1252.
58. Chatterjee M, Honemann D, Lentzsch S et al. In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway. Blood 2002;100:3311-3318.
59. Lauta VM. A review of the cytokine network in multiple myeloma. Cancer 2003;97:2440-2452.
60. Bisping G, Leo R, Wenning D et al. Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood 2003;101:2775-2783.
61. Mudry RE, Fortney JE, York T et al. Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy. Blood 2000;96:1926-1932.
62. Gibson LF. Survival of B lineage leukemic cells: signals from the bone marrow microenvironment. Leuk Lymphoma 2002;43:19-27.
63. Landowski TH, Olashaw NE, Agrawal D et al. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappaB (RelB/p50) in myeloma cells. Oncogene 2003;22:2417-2421.
64. Dalton WS. The tumor microenvironment: focus on myeloma. Cancer Treat Rev 2003;29(suppl 1):11-19.